Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* overall healthy subjects~* non-childbearing potential females included~Exclusion Criteria:~* history of significant sensitivity to any drug~* positive test for HAV IgM, HBsAg, anti-HCV Ab or anti-HIV Ab~* history of gastrointestinal issues or procedures~* history of seizures, diabetes or cancer (except basal cell carcinoma)~* clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder~* use of tobacco or nicotine-containing products with the 6-month period prior to study drug administration~* donation or loss of 550 mL or more blood volume or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration~* abnormal screening laboratory results that are considered clinically significant by the investigator~* current enrollment in another clinical study~* previous enrollment in this study~* recent (6-month) history of drug/alcohol abuse that could preclude adherence to the protocol~* pregnant or breastfeeding female~* requirement for any OTC and/or prescription medication, vitamins and/or herbal supplements on a regular basis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): ABT-450
- 2 (Type: PLACEBO_COMPARATOR): Placebo for ABT-450
- 3 (Type: ACTIVE_COMPARATOR): ABT-450/ritonavir
- 4 (Type: PLACEBO_COMPARATOR): Placebo for ABT-450/placebo for ritonavir

Based on this trial design, predict the completion outcome and termination type (if applicable).